NLR与PLR在非小细胞肺癌患者化疗疗效及预后评估中的价值

目的 探究外周血中性粒细胞与淋巴细胞比值(NLR)以及血小板与淋巴细胞比值(PLR)在非小细胞肺癌(NSCLC)患者化疗疗效及预后中的评估价值。方法 选择2019年3月—2021年6月我院收治87例NSCLC患者各项资料予以回顾性分析，患者在化疗治疗前均测定外周血中性粒细胞、淋巴细胞、血小板，并计算NLR与PLR,评估患者疗效及预后，分析NLR与PLR在患者化疗疗效及预后中的评估价值。结果 NLR、PLR水平与患者吸烟史、肿瘤分期、是否出现淋巴结转移有关(P<0.05);患者接受两个周期化疗后治疗有效率为71.26%,有效组患者NLR与PLR水平显著低于无效组(P<0.05);受试者工作特征曲线显示，NLR、PLR及两者联合用于评估患者化疗疗效曲线下面积分别为0.859、0.785、0.926;患者预后不良发生率为32.18%,单因素与多元Logistic回归分析显示分化程度、PLR、NLR与患者预后有关(P<0.05)。结论 外周血NLR、PLR与患者多项临床特征有关，不仅可用于患者评估患者化疗疗效，还与患者预后关系密切。

Value of peripheral blood neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluating chemotherapy response and prognosis of patients with NSCLC

Objective To investigate the value of peripheral blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in evaluating chemotherapy response and prognosis of patients with non-small cell lung cancer (NSCLC). Methods The data of 87 patients with NSCLC admitted to the hospital from March 2019 to June 2021 were retrospectively analyzed. Peripheral blood neutrophils, lymphocytes, and platelets were measured before chemotherapy to calculate NLR and PLR. The efficacy and prognosis were evaluated. The value of NLR and PLR in evaluating chemotherapy response and the prognosis was analyzed. Results NLR and PLR were related to smoking history, tumor stage, and lymph node metastasis (P<0.05). The effective rate was 71.26% after 2 cycles of chemotherapy, and NLR and PLR in the effective group were significantly lower than those in the ineffective group (P<0.05). The receiver operating characteristic curve showed that the areas under the curve of NLR, PLR alone and in combination to evaluate chemotherapy response were 0.859, 0.785, and 0.926, respectively. The incidence of poor prognosis was 32.18%. Univariate analysis and multivariate logistic regression analysis showed that differentiation degree, PLR and NLR were related to the prognosis (P<0.05). Conclusion Peripheral blood NLR and PLR are related to many clinical characteristics of patients with NSCLC. The two can be used to evaluate chemotherapy response and the prognosis.